Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancerHannelore Denys, Mona M. Van Steenberghe, Marc Martens et al.|Breast Cancer Research and Treatment|2020Cited by 44